Bing C. Wang
Director of Finance/CFO chez CELLECTIS S.A.
Fortune : - $ au 29/02/2024
Profil
Founder of Refuge Biotechnologies, Inc., Bing C.
Wang currently is Chief Financial Officer of Cellectis SA.
Dr. Wang previously occupied the position of Chief Executive Officer & Director at Refuge Biotechnologies, Inc. and Director-Healthcare Investment Banking at Barclays Capital, Inc.
Bing C.
Wang received an undergraduate degree from The Trustees of Columbia University in The City of New York, a doctorate and a graduate degree from Princeton University and an MBA from Columbia Business School.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
CELLECTIS SA
-.--% | 14/02/2023 | 0 ( -.--% ) | - $ | 29/02/2024 |
Postes actifs de Bing C. Wang
Sociétés | Poste | Début |
---|---|---|
CELLECTIS S.A. | Director of Finance/CFO | 10/02/2022 |
Anciens postes connus de Bing C. Wang
Sociétés | Poste | Fin |
---|---|---|
Refuge Biotechnologies, Inc.
Refuge Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA. | Founder | 01/12/2021 |
KBP Biosciences USA, Inc.
KBP Biosciences USA, Inc. Miscellaneous Commercial ServicesCommercial Services KBP Biosciences engages in conducting biotechnological research to develop therapies for patients. The company was founded by Huang Zhenhua in and is headquartered in Princeton, NJ. | Director/Board Member | 01/10/2018 |
Barclays Capital, Inc.
Barclays Capital, Inc. Investment Banks/BrokersFinance Barclays Capital, Inc. is a registered broker/dealer headquartered in New York City. The firm was founded in 1997 and is a subsidiary of Barclays Group US, Inc., ultimately owned by Barclays plc (LON: BARC) in Great Britain. Barclays Capital provides large corporate, government and institutional clients a full spectrum of prime brokerage services which includes equities and fixed income financing, OTC Clearing, Futures and Foreign Exchange Prime Brokerage and access to industry insights and analytics from their Strategic Consulting team. | Head of Private Banking | - |
Formation de Bing C. Wang
The Trustees of Columbia University in The City of New York | Undergraduate Degree |
Princeton University | Doctorate Degree |
Columbia Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
CELLECTIS S.A. | Health Technology |
Entreprise privées | 3 |
---|---|
Barclays Capital, Inc.
Barclays Capital, Inc. Investment Banks/BrokersFinance Barclays Capital, Inc. is a registered broker/dealer headquartered in New York City. The firm was founded in 1997 and is a subsidiary of Barclays Group US, Inc., ultimately owned by Barclays plc (LON: BARC) in Great Britain. Barclays Capital provides large corporate, government and institutional clients a full spectrum of prime brokerage services which includes equities and fixed income financing, OTC Clearing, Futures and Foreign Exchange Prime Brokerage and access to industry insights and analytics from their Strategic Consulting team. | Finance |
KBP Biosciences USA, Inc.
KBP Biosciences USA, Inc. Miscellaneous Commercial ServicesCommercial Services KBP Biosciences engages in conducting biotechnological research to develop therapies for patients. The company was founded by Huang Zhenhua in and is headquartered in Princeton, NJ. | Commercial Services |
Refuge Biotechnologies, Inc.
Refuge Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA. | Commercial Services |